Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sabatolimab + Spartalizumab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sabatolimab | MBG453|MBG-453|MBG 453 | Immune Checkpoint Inhibitor 150 TIM-3 Antibody 9 | Sabatolimab (MBG453) is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (PMID: 29544515, PMID: 31847708). | |
| Spartalizumab | PDR001|PDR-001 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03961971 | Phase I | Sabatolimab + Spartalizumab | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | Active, not recruiting | USA | 0 |